Sanofi India Q1 Results: EBITDA up 25% YoY, margin expands; net sales grow 4%

Sanofi India Q1 Results: EBITDA up 25% YoY, margin expands; net sales grow 4%Sanofi India's EBITDA rose 25% to ₹171.9 crore in Q4, with margins improving to 32.1%. Shares closed 2.3% higher at ₹6,066.55 on the BSE ahead of the earnings announcement.By Sheersh Kapoor May 14, 2025, 6:54:28 PM IST (Published)1 Min ReadSanofi India reported a mixed set of numbers for the March quarter, with a notable improvement in operational performance offsetting a decline in net profit.

For Q4 FY25, net profit fell 12.5% year-on-year to ₹119.5 crore, while revenue rose nearly 5% to ₹535.9 crore.

However, EBITDA saw a robust 25% jump to ₹171.9 crore, with margins expanding to 32.1% from 26.9% a year ago. The improvement was attributed to strong cost controls and operational efficiencies, according to the company.

The launch of Soliqua®, a new diabetes drug in the premix segment, contributed to growth and strengthened Sanofi's broader diabetes portfolio.

On a comparable basis of continuing business, net sales grew 4% for the quarter.

Also Read: Tata Power Q4 Results: Profit up 24% YoY, margin improves; ₹2.25 dividend proposed

“The Company has delivered a strong first quarter performance reflecting Sanofi’s successful strategy for India,” said Rachid Ayari, Whole Time Director and CFO. “We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of our best-in-class innovative products in India.”

Shares of Sanofi India closed 2.3% higher at ₹6,066.55 on the BSE ahead of the earnings announcement.Continue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsearningsQ1 resultsSanofi Indiashare market today